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Summary: Glycation and fluorescence at 440 nm (excitation at 370 nm) were found to be increased in immuno-
globulin G (IgG) from diabetics, strongly indicating the presence of IgG-linked advanced glycosylation end pro-
ducts. In contrast, levels of IgG-linked advanced glycosylation end products were low or undetectable in both
normal and diabetic subjects when an advanced glycosylation end products specific antibody was employed for
immunological determination of advanced glycosylation end products. Furthermore, no correlation exists between
IgG glycation, fluorescence and immunoreactivity. In diabetics, the Fc fragment of IgG showed decreased protein
A binding and decreased fixation of complement. This impairment of biological activity was not correlated with
the immunologically determined level of advanced glycosylation end products, whereas IgG-linked fluorescence
was inversely related to complement fixing activity. TTiese results indicate that mechanisms different from glycation
or browning are respoüsible for changes in the functional properties of IgG.
Introduction
In glycation, glucose reacts with free amino groups of
proteins to form labile Schiff bases, which subsequently
undergo Amadori rearrangemerit to stable ketoamines.
Formation tfAmädori products is well established for a
number of proteins and häs been found to be increased
in diabetes (föf a review see 1. c. (1)). The Amadori prod-
uct undergoes veiy slowly a seiies of still unknown re^
arrangement reactions to form yellow-brpwn, flüor^
escent and cross^linking substänces, called advanced
glycosylation end products. These bro\^ning products
are thought to accumulate on proteins and to play an
irnportaiit role in the development of diabetic late com-
plications (for ä review see 1. c. (2)).
Our recent studies indicate that glycation of immunoglo-
bulin G (IgG) in vitro leads to IgG fluorescence and
polymerization (3), concomitant with marked changes in
functional properties of the Fc fragment (4, 5). In view
of the possible pathophysiological relevance of these
findings, we examined the biological activity of the Fc
fragment of IgG from normal and diabetic subjects.
thermore, the possible involvement of IgG-linked ad-
vanced glycosylation end products was investigated with
the aid of an advanced glycosylation end products
specific enzyme-linked immunosorbent assay (ELISA).
Evidence is presented, indicating that the Fc fragment
pf IgG from diabetics is fimctionally impaired, and that
this impairment is unrelated to glycation or formation of
advanced glycosylation end products.
Materials and Methods
Materials
Bövine serum albumin, sheep blood and amboceptor 6000 were
from Behringwerke, Marburg/Lahn, Germany. The Glyco-Gel B
Test Kit was from Pierce, Oud-Beijerland, The Netherlands; the
enzyme immunoassay for determination of human IgG subclasses
from The Binding Site, Birmingham, U. K.; DEAE-cellulose (DE-
52) from Whatman BioSystems, Maidstone, U.K.; keyhole limpet
haemocyanin frorn Calbiochem, Bad Soden, Germany; peroxidase-
linked sheep anti-rabbit IgG from Boehringer, Mannheim, Germ-
any. All other chemicals were from Sigma, Deisenhofen, Germany,
or from E. Merck, Darmstadt, Germany.
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Methods
Serum was obtained from 43 normal healthy persons (ranging be-
twcen 21 and 58 years of age) and from 43 diabetic patients (17-
75 years old) attending thc outpatient Service for diabetic care of
the Hospital München-Schwabing, an Academic Hospital of the
University of Munich. Patients were included irrespective of type
of treatment. Informed consent was obtained from all subjects be-
fore venepuncture.
Immunoglobulin G from human serum was purified by precipi-
tation with (NH^SC^ and chromatography on DEAE-cellulose, äs
previously described (4). The purification procedure yielded highly
purified IgG preparations äs revealed by polyacrylamide gel elec-
trophoresis, sodium dodecyl sulphate polyacrylamide gel eleo
trophoresis and immunoelectrophoresis.
IgG was quantified in a Beckman Array protein System or by
measurement of absorbance at 280 nm. Human IgG subclasses l,
3 and 4 were determined by enzyme immunoassay according to
the supplier's instructions. The level of glycated IgG in percentage
of total IgG was measured by affmity chromatography (6) using
the Glyco-Gel B test kit. IgG (2 mg) was applied to the top of an
aminophenylboronic acid column and further processed according
to the supplier's instructions. Absorbance of bound and unbound
fractions was determined at 280 nm in a Shimadzu UV-260 spec-
trophotometer.
Advanced glycosylation end products were estimated by measure-
ment of IgG absorbance at 350 rim (7, 8) at a protein concentration
of l g/l in a Shimadzu UV-260 spectrophotometer. In addition,
IgG-linked fluorescence at 440 nm upon excitation at 370 nm (7,
8) was determined at an IgG concentration of 0.5 g/l in an Aminco-
Bowman spectrofluorometer. Absorbance at 350 rim and relative
fluorescence were expressed relative to the absorbance at 280 nm.
Advanced glycosylation end product proteins (derived from human
albumin, human IgG, human transferrin, bovine albumin and bov-
ine globulin) were prepared in vitro by incubating 43.3 >1/1 of
the respective protein for 34 days at 37 °C with 55.5 mmol/1 glu-
cose in 0.05 mol/1 2-amino-2-methyl-propanol-(l) buffer, pH 9.5,
containing 1.2 mmol/1 MgSO4, 5.4 mmol/1 KC1, 26.2 mmol/1
NaHCO3, 116 mmol/1 NaCl, 6 mmol/1 NaN3 and 10 mg/1 gentam-
icin, followed by dialysis against 154 mmol/1 NaCl. Poly-L-lysine
(Mr 15 000 to 30 000) (5 g/l) was incubated at 37 °C in the presence
of l .67 mol/1 glucose for 18 days in 2-amino-2-methyl-propanol-
(1) buffer.
Advanced glycosylation end products were detected immunochem-
ically essentially äs described by Nakayama et al. (9, 10). Briefly,
keyhole limpet haemocyanin (20 g/l) was incubated under sterile
conditions in the absence and presence of 2.2 mol/1 glucose at
37 °C in 0.4 mol/1 Na-phosphate buffer, pH 7.5, for twelve weeks.
After extensive dialysis against 154 mmol/1 NaCl, rabbits were im-
munized with l mg advanced glycated and non-glycated keyhole
limpet haemocyanin, respectively, emulsified in incomplete
Freundes adjuvant, followed by 7 booster injections at 2-week in-
tervals.
Antisera titres were determined in a non-competitive ELISA. Wells
of microtitre plates (Nunc immunoplates) were coated ovemight at
4 °C with 0.1 ml of advanced glycosylation end products protein,
0.5 mg/1 in 0.1 mol/1 carbonate buffer, pH 9.6. The wells were
washed with 154 mmol/1 NaCl containing 0.5 ml/l Tween 20, then
blocked with 5 g/l bovine serum albumin in phosphate-buffered
saline, pH 7.4. Rabbit antisera dilutions (0.1 ml) were added to the
wells and incubated for two hours at room temperature. Thereafter,
wells were washed again and developed with a peroxidase-conju-
gated anti-rabbit IgG from sheep, using o-phenylenediamine äs
Substrate. Absorbance at 450 nm was read on a Microplate reader
MR 6000 (Dynatech).
IgG-linked advanced glycosylation end products were assayed in
a competitive ELISA. Microtitre plates were coated by adding 0.1
ml human advanced glycosylation end products IgG, 0.5 mg/1, in
0.1 mol/1 carbonate buffer, pH 9.6. After incubation overnightj
wells were washed and blocked with 0.2 ml 5 g/l bovine serum
albumin in phosphate buffered saline, pH 7.4. Thereafter, 0.05 ml
of samples (IgG, 2 g/l) and 0.05 ml of l : 1000 diluted rabbit anti-
serum were added to the wells. Plates were incubated for 2 hours
at room temperature and overnight at 4 °C, and further processed
äs described for the non-competitive assay. A calibration curve was
prepared from serial l : 2 dilutions of human advanced glycosyl-
ation end products IgG, corresponding to IgG protein concen-
trations of 200 to 3. l mg/1. Relative fluorescence of the respective
dilutions ranged frorri 2 to 0.03- Immunoreactivity of samples was
read from the calibration curve and was expressed äs advanced
glycosylation end products units, one advanced glycosylation end
products unit corresponding to the ariipunt of antibody-reactive
material found in Standard advanced glycosylation end products
IgG at a protein concentration of l mg/1 (l advanced glycosylation
end products unit = l mg/1 advanced glycosylation end products
IgG protein). The calibration curve was linear frorh 6 to 100 ad-
vanced glycosylation end products units. Determinations were run
in triplicate. The intra-assay coefflcient of Variation was 7.1%
(je = 118 advanced glycosylation end products units, n = 16),
while the inter-assay coefficient of Variation was 10.8% (X = 23
advanced glycosylation end products units, n = 31) and 12%
(X = 7.4 advanced glycosylation end products units, n = 28).
Protein A reactivity arid complement (C) fixation were determined
äs described previously (5). Statistical evaluation was perfbrrned
according to the instructions of Sachs (11). Statistical significance
was calculated by Studenfs tatest for unpaired data. Results are
given äs mean values ± SD.
Results
Immunoglobulin G was prepared from sera from 43
non-diabetic apparently healthy subjects, äs well äs from
43 diabetic patients displaying mean HbAlc levels of
5% (ränge 3.9%-5.6%) and 9% (ränge 4.6%-13.7%),
respectively. The IgG concentration was found to be es-
sentially the same in normal and diabetic sera (10.6
± 1.9 g/l and 10.7 ± 2.3 g/l). Furthermore, IgG sub-
classes l, 3 and 4 were determined in the preparations.
No difference in the content of IgG subclasses was ob-
served.
Levels of glycated IgG were found to be markedly in-
creased in diabetic patients äs revealed by affinity chro-
matography on boronate gel. Expressed äs a percentage
of total IgG (in analogy with HbAlc), glycation am-
ounted to 4.1 ± 0.87% (ränge 2.2%-5.7%, n == 43) and
10.3 ± 4.5% (ränge 2.9%-21.1%, n = 43, p < 0.0005)
im normal and diabetic subjects, respectively. A clear
correlation (r = 0.705) was demonstrable between
HbAle and glycated IgG in diabetics (data -not shown).
The possible occurrence of protein-bound brown and/or
fluofescent chromophores, indicäting the formation of
advanced glycosylation end products (7, 8), was investir
gated by measurement of absorbanee at 350 nm and of
fluorescence at 440 nm upon excitation at 370 nm. As
revealed by determination of absorbance at 350 nm, IgG
browning was essentially the same in normal and dia-
betic subjects, amounting to 3%6 ± 1.56 and 3.7 ± 1.98
(103 X A 350 nm/A280 nua^h = 15). In conträst, IgG
Eur. J. Clin/Chem. Clin. Biochem. / Vol. 32.1994 /Nö. 5
Dolhofer-Bliesener et al.: Impairment of Fc fragment function in diabetics is unrelated to glycation 331
0.3
0)O
l
co
0.2-
O.H
oo
o
o
00
o
o
QflQ
o
000
oooo
o
o
00
o
000
o
Normal Dlabelic
controis patients
Fig. l IgG-linked fluorescence in normal (·) and diabetic (O)
subjects.
In purified IgG (0.5 g/l), fluorescence at 440 nm upon excitation
at 370 nm was measured and related to absorbance at 280 nm.
Mean values are indicated by the horizontal bars.
fluorescence was markedly elevated in diabetic patients,
äs shown in figure l. Mean values of the ratio of fluor-
escence to absorbance at 280 nm were 0.148 (SD
= 0.026, n = 31) in controis and 0.19 (SD = 0.063,
n = 31, p < 0.0025) in diabetics. Absorbance at 350 nm
and the relative fluorescence wefe independent of the
age of the patients. In controis and diabetics no inter^
relationship was found between glycated IgG and ab-
sorbance at 350 nm, between glycated IgG and relative
fluorescence, or between absorbance at 350 nm and rela-
tive fluorescence.
Since browning products are not specifically assayed by
measurement of fluorescence, antibodies against ad-
vanced glycated keyhole limpet haemocyanin were pre-
pared essentially according to I.e. (9). The properties
and specificity of the antibody were very similar to those
described by Nakayama et al. (9) for anti-advanced gly-
cated keyhole limpet haemocyanin antibody, and by
others, using advanced glycosylation end products de-
rived from bovine serum albumin or from ribonuclease
äs antigen (12, 13). A non-competitive ELISA showed
that antiserum from a rabbit immunized with advanced
glycated keyhole limpet haemocyanin reacted with ad-
vanced glycosylation end products derived from human
IgG, albumin, transferrin and from bovine albumin and
globulin (fig. 2). A weak reaction was also observed
with unmodified proteins, indicating the presence of low
amounts of advanced glycosylation end products struc-
tures in native proteins, generated from in vivo glycated
proteins or during storage (14). Neither advanced glyco-
sylation end products proteins nor native proteins gave
a reaction with antisera from rabbits immunized with
keyhole limpet haemocyanin incubated in the absence
of glucose.
To determine the specificity of the anti-advanced glyco-
sylation end products antibody, unmodified proteins, ad-
2000 4000 8000
Antiserum [dilution]
2000 4000 8000
-1
Fig. 2 Dilution curves for antisera to advanced glycated keyhole
limpet haemocyanin and to keyhole limpet haemocyanin.
Wells of microtitre plates were coated with native and in vitro
glycated human albumin.(a), human IgG (b), human transferrin (c),
bovine albumin (d) and bovine globulin (e). Immunoreactivity was
determined in a non-competitive ELISA äs described in Materials
and Methods.
Reaction of:
(·) native protein with advaoced glycated keyhole limpet haemo-
cyanin antiserum
(O) advanced glycosylation end products protein with advanced
glycated keyhole limpet haemocyanin antiserum
(A) native protein with keyhole limpet haemocyanin antiserum
( ) advanced glycosylation end products protein with keyhole lim-
pet haemocyanin antiserum
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Fig. 2 (continued)
Reaction of:
(O) native protein with advanced glycated keyhole limpet haemo-
cyanin advanced antiserum
(O) advanced glycosylation end products protein with advanced
glycated keyhole limpet haemocyanin antiserum
(A) native protein with keyhole limpet haemocyanin antiserum
( ) advanced glycosylation ehd produets protein with keyhole lim-
pet haemocyanin antiserum
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Fig. 3 ELISA competitive Inhibition curves for advanced glyco-
sylation end products proteins.
Microtitre plates were coated with 0.5 mg/1 advanced glycosylation
end products human albumin. Competitors were added to the welis
at the concentrations given on the abscissa and further processed
in a competitive ELISA äs described in Materials and Methods.
Results were expressed äs B/B0, where B is sample absorbance and
BÖ is absorbance in the absence of competitor (total absorbance).
Advanced glycosylation end products protein derived frorn
(o) human albumin
(O) human IgG
(A) human transferrin
( ) bovine albumin
(a) bovine globulin
Nearly identical results were obtained when microtitre plates were
coated with advanced glycosylation end products IgG:
vanced glycosylation end products proteins and poly-Z,-
lysine were tested in a competitive assay. Figure 3 shows
ELISA competition curves for anti-advanced glycated
keyhole limpet haemocyanin-antiserum. It can be seen
that advanced glycosylation end products derived from
human and bovine albumin showed the greatest inhi-
bition, while the weakest Inhibition was shown by ad-
vanced glycosylation end products derived from human
transferrin. The Inhibition curves of different advanced
glycosylation end products proteins were parallel to
each other.
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Fig. 4 Increase in immunoreactivity äs a function of incubätion
time.
Microtitre plates were coated with 0.5 mg/1 advanced glycosylation
end products derived from human albumin. Native human IgG (·)
and IgG incubated with glucose for 3 (O), 9 (A), 18 ( ) and 34
(·) days, respectively, was added to the wells at the concentrations
given on the abscissa and further processed in a competitive ELISA
äs described in Materials and Methods. Nearly identical results
were obtained when plates were coated with advaneed glycosyla-
tion end products derived from IgG.
Immunorogical reactivity of proteins glycated in vitro
increased with the time of incubätion with ghicose (flg.
4). Furthermore, poly-£-lysine incubated with glucose
showed marked Inhibition in competitive ELISA, while
no competition for antibody binding was disceraible
from the starting material or from poly-Z-lysine incu-
bated withöut glucose (fig. 5). In ordef to establish
whether Schiff bases or Amadori products are recog*
nized by the antibody, advanced glycosylation end prod-
ucts proteins were reduced with NaBH4. After redüction,
the immunoreaetivity of advanced glycosylation end
products proteins remained essentially unchanged (data
not shown), indicating that -eariy glycätion products,
Eur. J. Clin/Chern. Clin. Biochern. / Vol. 32.1994 /No. 5
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Fig. 5 ELI S A competitive Inhibition curve for advanced glycosy-
lation end products derived from poly-L-lysine.
Microtitre plates were coated with 0.5 mg/1 advanced glycosylation
end products derived from human albumin. The competitor was
poly-Zr-lysine: starting material in the absence (·) and presence (O)
of glucose; after 18 days of incubation in the absence (A) and
presence (Δ) of glucose. Nearly identical results were obtained
when wells were coated with advanced glycosylation end products
derived from IgG.
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Fig. 7 Levels of immunologically determined advanced glycosy-
lation end products in IgG from normal controls (o) and diabetic
patients (O).
The horizontal lines indicate the detection limit of the ELISA.
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Schiff bases and Amadori products, were not the anti-
genic epitopes.
The relationship between fluorescence and immunoreac-
tivity during in vitro incubation is shown in figure 6.
A time-dependent increase in fluorescence concomitant
with an increase in immunoreactivity was observed in
albumin samples incubated with glucose. It is note-
worthy that an approximate twofold increase in fluor-
escence occurred in samples incubated without glucose,
while no change in irnrn noreactivity was detected.
160
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Fig. 6 Increase in immunoreactivity and relative fluorescence
during glucose incubation.
Human albumin was incubated in the absence (triangles) and pres-
ence (circles) of glucose. At the times indicated on the abscissa,
relative fluorescence (open Symbols) and immunological reactivity
(closed symbols) were determined s described in Materials and
Methods.
In order to determine whether fluorescence of IgG from
normal and diabetic subjects is related to IgG immuno-
reactivity, the protein-bound advanced glycosylation end
produets content of purified IgG was examined in a
competitive ELISA. Unexpectedly, IgG preparations
contained only small amounts, if any, of immunolog-
ically reactive material (fig. 7), which was 3 to 5 times
lower than expected from the measurement of IgG-
linked fluorescence.
Furthermore, IgG-linked advanced glycosylation end
products levels were found to be higher in normal con-
trols than in diabetics. In 8 out of 38 normal subjects,
and in 29 out of 38 diabetics, advanced glycosylation
end products values were lower than the detection limit
(6 advanced glycosylation end products units). Immuno-
logically determined levels of IgG-linked advanced gly-
cosylation end products were not correlated with gly-
cated IgG or with IgG-linked fluorescence (fig. 8). In
this connection, it is noteworthy that no immunolog-
ically reactive material could be detected in albumin
purified from 5 normal and 5 diabetic sera, although
these albumins showed high fluorescence at 440 nm
upon excitation at 370 nm (data not shown).
In order to investigate possible functional changes of
diabetic IgG, binding of protein A and complement fix-
ation, both occurring within the Fc fragment of IgG,
were rrieasured. In diabetics, a statistically significant
decrease in protein A reactivity was observed; 53 μg
(SD = 16.9, n = 40) and 45 μg (SD = 13.7, n = 41) of
IgG were bound by 12.5 μg of protein A in normal and
diabetic subjects, respectively (p < 0.0125). Finally, a
complement fixation test revealed a decrease in comp-
lement fixing activity of IgG from diabetics. In normal
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32.1994 / No. 5
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Fig. 8 Lack of correlation between immunologically determined ative fluorescence (b), respectively, in normal controls (·) and dia-
advanced glycosylation end products and glycated IgG (a) and rel- betic patients (O).
(n = 76 (a) and 62 (b)).
controls, complement fixation amounted to 70 ±21%
(n = 43), whereas in diabetics the mean value was found
to be 59 ± 27% (n = 42, p < 0.025); in five out of 42
diabetics C'-fixation was almost abolished. This decrease
in C'-fixation was apparently independent of the age of
the patients, the IgG subclass content of the sample, the
IgG concentration in serum, the level of blood glucose,
cholesterol, triacylglycerols, HbAlc, glycated IgG, the
absorbance at 350 nm, or the amount of immunolog-
ically determined advanced glycosylation end products.
However, a relationship between C'-fixation and IgG
fluorescence was observed in diabetic patients. It is evi-
dent from figure 9 that fluorescence and C'-fixation are
inversely correlated. Using IgG from diabetics, it was
found that C'-fixation values < 40%, between 40% and
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Relationship between IgG-linked fluorescence and com-«
fixing activity of immunoglobulin G from normal (·) and
(O) subjects.
80% and > 80% were ssoci ted with relative fluor-
escence values of 0.244 ± 0.062 (n = 7), 0.186 ± 0.061
(n = 14) and 0.15 ± 0.037 (n = 10), respectively. The
difference between each group of diabetics is statisti-
cally significant (p < 0.05), whereas in normal controls
no difference was discernible.
Discussion
Until recently, advanced glycosylation end products
were estimated by indirect, non-specific assays such s
measurement of the decrease in solubility (15), of resist-
ance to heat denaturation (16), of absorbance at 350 nm
and of fluorescence at 440 nm upon excitation at 370
nm (7, 8). Furthermore, 2-(2-furoyl)-4(5)-(2-furanyl>
IH-imidazole (17, 18), 5-hydroxy-methyi-l-alkylpyr-
role-2-carbaldehyde (pyiraline) (19), imidazo[4,5-b]pyr-
idinium (pentosidine) (20) and 3-deoxyfructose and 3-
deoxyglucosone (21) were claimed to represent ad-
vanced glycosylation end products formed in vivo and
to be present in human serum proteins and tissues. How-
ever, detection of single possible advanced glycosylation
end products substances in vivo is difficylt and cumber-
some, since a large number of different brpwning prod-
ucts is known (22). Nakayama et al. (9) introduced an
antibody for immunological detefmination of advanced
glycosylation end products. An antibody of comparable
specificity was prepared in our laboratory and used in
the present study. This antibody recognizes epitopes
which are formed in a time-dependent fashion during
incubation of proteins and amino acids with glucose in
vitro. These immunologically reactive structures display
fluorescenee and browning and are not reducible by
NaBH4, suggesting the formation of a commoii d-
vaneed glycosylation end products structure(s) by incu-
Eur. J. Clin.'Ghein. Olin. Biophem. / Vol. 32.1994 /No. 5
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bation of proleins or amino acids with glucose, whose
nature, however, is not yet known. In this connection it
is noteworthy that neither 2-(2-furoyl)-4(5)-(2-ftiranyl)-
IH-imidazole nor pyrraline or pentosidine react with an
antibody against advanced glycosylation end products
proteins (9, 12, 13).
From the results of the measurement of IgG-linked flu-
orescence, it was expeoted that the subsequently meas-
ured levels of immunologically reactive material in IgG
preparations would lie well within the ränge of the cali-
bration curve employed. However, immunoreactivity in
IgG, äs well äs in albumin, was low or undetectable,
being higher in normals than in diabetic subjects. This
suggests that serum proteins, like IgG or albumin, con-
tain little if any browning products. Possibly, advanced
glycosylation end products cannot be formed in con-
siderable amounts because of the short halflife of the
serum proteins, or because advanced glycosylation end
products serum proteins are rapidly cleared from the cir-
culation by the advanced glycosylation end products re-
; ceptor (23). Further, the possibility exists that the epi-
; tope(s) formed in vitro do not occur in vivo.
It seems reasonable to assume that the marked increase
in fluorescence of IgG from diabetics is due to mechan-
isms other than glycation and browning. Fluorescence
can result from the reaction between lipid peroxidation
products and proteins (24) and from the oxidation of
amino acids by free radicals (25, 26). It is known that
lipid peroxide levels are increased in diabetics (27, 28).
Furthermore, it has been demonstrated that early glyc-
ation products, Schiff bases and Amadori products, can
generate free radicals (29—31). In addition, äs shown by
Wolffl Hunt and coworkers (32—34), glucose itself can
produce free radicals via auto^oxidation. From these re-
ports one can conclude that an increase in free radical-
mediated oxidation of proteins might occur in hyper-
glycaemic diabetics.
With respect to the biological activity of IgG from dia-
betics, to our knowledge we have shown for the first
time that certain functional properties of the Fc region
of IgG from diabetics are impaired, i. e. there is a de-
crease in binding of protein A and fixation of comp-
lement to the Fc fragment, which probably contributes
to the increased susceptibility to infections, known to
occur in poorly controlled diabetics (35). The reasons for
the changes in the functional properties are unknown.
Interaction with protein A and fixation of complement
depend on the integrity of the region 230 to 270 of the
heavy chains (36), allowing structural changes of the Fc
fragment äs a prerequisite for complement binding. One
might speculate that oxidation of amino acids in the Fc
region by free radical mechanisms is responsible for
damage of the complement binding site, leading to an
alteration of biological activity.
The possibility that oxidative mechanisms rather than
glycation or browning reaction might be responsible for
the impaired Fc fragment function is supported by the
fact that the changes in functional properties are not cor-
related with the degree of glycation of IgG, absorbance
at 350 nm, or immunoreactivity, whereas an inverse re-
lationship was found between IgG-linked fluorescence
and complement fixing activity.
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